Patents by Inventor Venkataraman Sriram
Venkataraman Sriram has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124588Abstract: Provided herein are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, comprising disabling myeloid cells using an anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody.Type: ApplicationFiled: July 28, 2023Publication date: April 18, 2024Inventors: Christopher CHAN, Caroline Gray HACKETT, Venkataraman SRIRAM, Mark Bryan HEADLEY, Tiep Tu LE
-
Publication number: 20240084000Abstract: Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.Type: ApplicationFiled: December 19, 2022Publication date: March 14, 2024Inventors: Nadine Jahchan, Michel Streuli, Xi Yang, Linda Liang, Venkataraman Sriram, Joshua Pollack, Kara Mojica, Vladislava Juric, Linnea Haeggblom, Leonard G. Presta, Sayantan Mitra
-
Publication number: 20230287110Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.Type: ApplicationFiled: October 7, 2022Publication date: September 14, 2023Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
-
Patent number: 11572407Abstract: Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.Type: GrantFiled: November 18, 2021Date of Patent: February 7, 2023Assignee: PIONYR IMMUNOTHERAPEUTICS, INC.Inventors: Nadine Jahchan, Michel Streuli, Xi Yang, Linda Liang, Venkataraman Sriram, Joshua Pollack, Kara Mojica, Vladislava Juric, Linnea Haeggblom, Leonard G. Presta, Sayantan Mitra
-
Patent number: 11505602Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.Type: GrantFiled: October 14, 2019Date of Patent: November 22, 2022Assignee: PIONYR IMMUNOTHERAPEUTICS, INC.Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
-
Publication number: 20220153832Abstract: Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.Type: ApplicationFiled: November 18, 2021Publication date: May 19, 2022Inventors: Nadine Jahchan, Michel Streuli, Xi Yang, Linda Liang, Venkataraman Sriram, Joshua Pollack, Kara Mojica, Vladislava Juric, Linnea Haeggblom, Leonard G. Presta, Sayantan Mitra
-
Publication number: 20210317211Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, using an anti-TREM2 antibody or antigen binding fragment thereof.Type: ApplicationFiled: June 10, 2021Publication date: October 14, 2021Inventors: Michel Streuli, Leonard G. Presta, Venkataraman Sriram, Aritra Pal, Nadine Jahchan, Mikhail Binnewies, Joshua L. Pollack, Xiaoyan Du
-
Publication number: 20210101983Abstract: Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen binding fragment thereof.Type: ApplicationFiled: October 8, 2020Publication date: April 8, 2021Inventors: Christopher Chan, Aritra Pal, Venkataraman Sriram, Leonard G. Presta, Tiep Tu Le, Linda Liang
-
Patent number: 10836828Abstract: Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen binding fragment thereof.Type: GrantFiled: April 17, 2020Date of Patent: November 17, 2020Assignee: PIONYR IMMUNOTHERAPEUTICS, INC.Inventors: Christopher Chan, Aritra Pal, Venkataraman Sriram, Leonard G. Presta, Tiep Tu Le, Linda Liang
-
Publication number: 20200255529Abstract: Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen binding fragment thereof.Type: ApplicationFiled: April 17, 2020Publication date: August 13, 2020Inventors: Christopher CHAN, Aritra PAL, Venkataraman SRIRAM, Leonard G. PRESTA, Tiep Tu LE, Linda LIANG
-
Publication number: 20200247889Abstract: Provided herein are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, comprising disabling myeloid cells using an anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody.Type: ApplicationFiled: August 7, 2018Publication date: August 6, 2020Inventors: Christopher CHAN, Caroline Gray HACKETT, Venkataraman SRIRAM, Mark Bryan HEADLEY, Jr., Tiep Tu LE
-
Publication number: 20200140546Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.Type: ApplicationFiled: October 14, 2019Publication date: May 7, 2020Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
-
Patent number: 10508148Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.Type: GrantFiled: May 9, 2019Date of Patent: December 17, 2019Assignee: Pionyr Immunotherapeutics, Inc.Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
-
Publication number: 20190309064Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.Type: ApplicationFiled: May 9, 2019Publication date: October 10, 2019Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
-
Publication number: 20190298826Abstract: A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a PD-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or immune modulation through PD-1 is beneficial, eg. cancer.Type: ApplicationFiled: June 29, 2018Publication date: October 3, 2019Inventors: Axel Hoos, Keith W. Orford, Patrick Chun, Venkataraman Sriram, Elaine M. Pinheiro, Scot W. Ebbinghaus
-
Patent number: 10010608Abstract: A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a PD-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or immune modulation through PD-1 is beneficial, e.g., cancer.Type: GrantFiled: May 28, 2014Date of Patent: July 3, 2018Assignees: MERCK SHARP & DOHME CORP., NOVARTIS AGInventors: Axel Hoos, Keith W. Orford, Patrick Chun, Venkataraman Sriram, Elaine M. Pinheiro, Scot W. Ebbinghaus
-
Publication number: 20180044418Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and suberoylanilide hydroxamic acid (SAHA), and the use of the combination therapies for the treatment of caner.Type: ApplicationFiled: March 15, 2016Publication date: February 15, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Elaine M. Pinheiro, Ronan O'Hagan, Venkataraman Sriram, Joe Phillips
-
Patent number: 9827309Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and the CDK inhibitor dincaciclib, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.Type: GrantFiled: August 15, 2014Date of Patent: November 28, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Peter Richard Strack, Robert Booher, Venkataraman Sriram, Joseph H. Phillips
-
Publication number: 20160193334Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and the CDK inhibitor dincaciclib, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.Type: ApplicationFiled: August 15, 2014Publication date: July 7, 2016Applicant: MERCK SHARP & DOHME CORP.Inventors: Peter Richard Strack, Robert Booher, Venkataraman Sriram, Joseph H. Phillips
-
Publication number: 20160106835Abstract: A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and a PD-1 antagonist; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or immune modulation through PD-1 is beneficial, e.g., cancer.Type: ApplicationFiled: May 28, 2014Publication date: April 21, 2016Applicants: MERCK SHARP & DOHME CORP., GLAXOSMITHKLINE LLCInventors: Axel Hoos, Keith W. Orford, Patrick Chun, Venkataraman Sriram, Elaine M. Pinheiro, Scot W. Ebbinghaus